DE69617896T2 - Humaner monoklonaler Antikörper gegen VEGF - Google Patents

Humaner monoklonaler Antikörper gegen VEGF

Info

Publication number
DE69617896T2
DE69617896T2 DE69617896T DE69617896T DE69617896T2 DE 69617896 T2 DE69617896 T2 DE 69617896T2 DE 69617896 T DE69617896 T DE 69617896T DE 69617896 T DE69617896 T DE 69617896T DE 69617896 T2 DE69617896 T2 DE 69617896T2
Authority
DE
Germany
Prior art keywords
monoclonal antibody
antibody against
human monoclonal
against vegf
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69617896T
Other languages
English (en)
Other versions
DE69617896D1 (de
Inventor
Hisayoshi Ooka
Izumi Mita
Ayako Watanabe
Shiro Takagi
Noboru Satozawa
Tomoko Yokomatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Chemicals Inc
Original Assignee
Mitsui Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Chemicals Inc filed Critical Mitsui Chemicals Inc
Application granted granted Critical
Publication of DE69617896D1 publication Critical patent/DE69617896D1/de
Publication of DE69617896T2 publication Critical patent/DE69617896T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69617896T 1995-08-21 1996-08-16 Humaner monoklonaler Antikörper gegen VEGF Expired - Fee Related DE69617896T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21145495 1995-08-21
JP6660196 1996-03-22

Publications (2)

Publication Number Publication Date
DE69617896D1 DE69617896D1 (de) 2002-01-24
DE69617896T2 true DE69617896T2 (de) 2002-04-25

Family

ID=26407800

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69617896T Expired - Fee Related DE69617896T2 (de) 1995-08-21 1996-08-16 Humaner monoklonaler Antikörper gegen VEGF

Country Status (3)

Country Link
US (1) US5730977A (de)
EP (1) EP0787742B1 (de)
DE (1) DE69617896T2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
WO2000035956A1 (fr) * 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
ES2694002T3 (es) * 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
ATE425255T1 (de) * 2000-03-31 2009-03-15 Imclone Systems Inc Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
IL156306A0 (en) 2000-12-21 2004-01-04 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
EP1443961B1 (de) * 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein-zusammensetzungen
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
EP2281885A1 (de) 2003-08-27 2011-02-09 Ophthotech Corporation Kombinationstherapie zur Behandlung von neovaskulären Augen-Erkrankungen
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7598080B2 (en) * 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
EP2500063A1 (de) 2005-02-03 2012-09-19 TopoTarget UK Limited Kombinationstherapie mit HDAC-Hemmern und Melphalan zur Behandlung von Krebs
ES2540204T3 (es) 2005-05-13 2015-07-09 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
EP1957056A2 (de) 2005-11-10 2008-08-20 TopoTarget UK Limited Histondeacetylase (hdac) hemmer (pxdlol) zur behandlung von krebs allein oder in kombination mit chemotherapeutika
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
SI2066694T1 (sl) 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
CU23636A1 (es) 2006-11-01 2011-03-21 Ct Ingenieria Genetica Biotech Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
JP2010540426A (ja) 2007-09-25 2010-12-24 トポターゲット ユーケー リミテッド 特定のヒドロキサム酸化合物の合成方法
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
JP6041489B2 (ja) 2008-11-22 2016-12-07 ジェネンテック， インコーポレイテッド 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
US20100266589A1 (en) * 2009-04-20 2010-10-21 Eric Hedrick Adjuvant cancer therapy
TW201431558A (zh) * 2009-08-15 2014-08-16 建南德克公司 用於治療先前治療過之乳癌之抗-血管新生療法
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
EP3064509A3 (de) 2010-02-23 2016-11-02 F. Hoffmann-La Roche AG Anti-angiogenese-therapie für die behandlung von ovarialkarzinom
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CU23895B1 (es) 2010-12-28 2013-05-31 Biorec Sa Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
EP3590965A1 (de) 2011-03-29 2020-01-08 Roche Glycart AG Antikörper-fc-varianten
HUE042192T2 (hu) 2011-09-23 2019-06-28 Oncomed Pharm Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
US20150017163A1 (en) 2013-07-12 2015-01-15 Ophthotech Corporation Methods for Treating or Preventing Ophthalmological Conditions
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
JP6967003B2 (ja) 2015-09-23 2021-11-17 メレオ バイオファーマ ５ インコーポレイテッド がんの処置のための方法および組成物
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002067A1 (en) * 1988-11-09 1990-05-09 Tamotsu Fukuda Parent cell line for producing human hybridomas
ATE348110T1 (de) * 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist

Also Published As

Publication number Publication date
EP0787742A1 (de) 1997-08-06
US5730977A (en) 1998-03-24
EP0787742B1 (de) 2001-12-12
DE69617896D1 (de) 2002-01-24

Similar Documents

Publication Publication Date Title
DE69617896D1 (de) Humaner monoklonaler Antikörper gegen VEGF
DE69637408D1 (de) Antikörper gegen cd-80
FI956112A (fi) Monoklonaalinen anti- V-integriinivasta-aine
NO980915L (no) Rekombinante anti-CD4-antistoff egnet for human terapi
ATE458008T1 (de) Humane monoklonale antikörper gegen ctla-4
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DE69519878D1 (de) Intrafokaler dübel
DE29502052U1 (de) Dübel
DE59602501D1 (de) Verschlussteil
DE69322847T2 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
DE69611468D1 (de) Elektrophotographisches Gerät
DE69223606D1 (de) Humaner monoklonaler antikörper gegen glycoprotein-iib/iiia
DE69616587T2 (de) Schliessvorrichtung
DE69631941D1 (de) Elektrophotographisches Gerät
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE29501664U1 (de) Auftragvorrichtung
DE29604095U1 (de) Sektionaltor
DE69615727D1 (de) Fünfstufige Xerografievorrichtung
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
ATE290074T1 (de) Monoklonaler antikörper gegen humanes mp52
DE29512719U1 (de) Monoklonale Antikörper gegen humanes Interleukin-10
DE29512497U1 (de) Dübel
DE29512115U1 (de) Verschließvorrichtung
DE29502628U1 (de) Blindenstock
BR9609863A (pt) Fecho

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee